Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura
{"title":"Prevalencia de hidrosadenitis supurativa en pacientes con espondiloartritis axial","authors":"Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura","doi":"10.1016/j.reuma.2024.501808","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.</div></div><div><h3>Patients and methods</h3><div>We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.</div></div><div><h3>Results</h3><div>A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs. 18%; <em>P</em>=.005), greater disease activity according to BASDAI (5.6<!--> <!-->±<!--> <!-->2.3 vs. 3.2<!--> <!-->±<!--> <!-->2.1; <em>P</em>=.026), less structural damage according to the axial BASRI (1.5<!--> <!-->±<!--> <!-->1.3 vs. 5.5<!--> <!-->±<!--> <!-->3.5; <em>P</em><.018) and shorter time since diagnosis of AxSpA (14.7<!--> <!-->±<!--> <!-->2.6 vs. 27.8<!--> <!-->±<!--> <!-->13.5 years; <em>P</em>=.001). No significant differences were found for the remaining variables studied.</div></div><div><h3>Conclusion</h3><div>This study suggests that prevalence of HS in patients with AxSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 501808"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X24001293","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.
Patients and methods
We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.
Results
A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs. 18%; P=.005), greater disease activity according to BASDAI (5.6 ± 2.3 vs. 3.2 ± 2.1; P=.026), less structural damage according to the axial BASRI (1.5 ± 1.3 vs. 5.5 ± 3.5; P<.018) and shorter time since diagnosis of AxSpA (14.7 ± 2.6 vs. 27.8 ± 13.5 years; P=.001). No significant differences were found for the remaining variables studied.
Conclusion
This study suggests that prevalence of HS in patients with AxSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.
期刊介绍:
Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.